Mercury Systems: A Long-Term Owner's Study

How it gets paid. Part of revenue is recognized upon product delivery, and part is recognized over time on long-term contracts as performance progresses. Of FY2025 revenue, 53% was recognized at a point in time and 47% over time; for FY2024 the split was 45% and 55%. Over-time revenue comes mainly from long-term contracts to develop, manufacture, or modify complex modules and subsystems, many of which involve fixed-price contracts and estimates at completion. In its FY2025 annual report the company listed the "total cost estimates" on such contracts as a critical audit matter, which means profit and gross margin are fairly sensitive to changes in those estimates.

Whether revenue is recurring, stable, and predictable. The underlying demand for this business is relatively stable, because defense programs have long life cycles, and the company's backlog at the end of FY2025 was roughly $1.4 billion, of which $807.8 million was expected to convert to revenue within the next 12 months. On the other hand, predictability is undermined by two things: first, the timing volatility of orders and program deliveries; second, the estimation, manufacturing, and delivery-execution risk on fixed-price development and integration contracts. In short, demand has a degree of continuity, but reported results are not highly predictable.

Cost structure. This is a classic "engineering R&D + manufacturing capability + program execution" business. It must sustain R&D while maintaining plants, quality systems, supply chains, and security and compliance capabilities. For a company like this, fixed costs are not low, and once program execution slips, yields falter, materials are scrapped, or warranty costs rise, gross margin comes under pressure quickly. FY2024 gross margin dropped sharply to 23.5%, which the company attributed clearly to EAC changes, inventory reserves, warranty, scrap, and manufacturing adjustments; FY2025 recovered to 27.9% but still has not returned to the 40%+ level of FY2021–FY2022.

Dependencies and how understandable it is. This business is not so complex that it cannot be understood; the truly hard part is that it is not a consumer product or software subscription, but high-specification defense electronics + program-based contract execution + long-cycle qualification and reliability requirements. It clearly depends on a few large customers, on defense budgets and continuing resolutions, on clearing security and compliance thresholds, and on management's meticulous control of manufacturing and program execution. A long-term owner can understand it, but must understand four sets of logic at once: engineering, contract accounting, supply chain, and military procurement.

Would I hold this business if the stock market closed for 5 years. The business itself: at a lower price, I would track or even hold it. At the current price: I would not. The reason is not a lack of demand, but that it has not yet proven it possesses sufficiently stable high returns and high-quality cash flow, while the current price already prices in a script of "a smooth recovery, a clear margin lift, and sustained cash-flow delivery."

Business understandability score: 4/5.

Industry and Competitive Landscape

Fact. Mercury operates in the aerospace and defense electronics arena. In its 2025 annual report the company emphasized that its products are deployed across more than 300 programs in 35 countries; its customers include nearly all the major A&D primes. Behind the industry's long-term demand are rising global defense spending, the electronification of platforms, edge computing, open architectures, and growing demand for secure processing. According to SIPRI, global military expenditure reached $2.887 trillion in 2025, up 2.9% in real terms, the 11th consecutive year of growth; the U.S. FY2027 defense budget documents likewise continue to prioritize procurement and research, development, test and evaluation.

Inference. This looks more like a long-term-growth but heavily regulated, heavily qualified, heavily program-driven industry than a typical cyclical industrial-goods sector. Long-term demand is not poor, but industry profitability is not inherently high, because military procurement emphasizes competitive bidding, quality, delivery schedules, traceability, and cost compliance. Bidding, design-in, the transition from program to volume production, and subsequent technology refreshes all affect the economics. The company itself acknowledges that competition is intensifying, that customers can pass competitive pressure down the supply chain, and that consolidation among large competitors brings stronger bargaining power.

Main competitors. In the peer group of its shareholder-return comparison chart, Mercury lists several comparable names, including Curtiss-Wright, Leonardo DRS, Kratos, MACOM, OSI Systems, and AeroVironment. From the angle of "stronger, and more worthy of a long-term owner's comparison," Curtiss-Wright is a better reference: it achieved record sales, profit, and free cash flow in 2025, while MRCY is still in its recovery phase.

The company's position in the industry. Mercury's advantage lies not in being the largest, but in its integrated capability across high-reliability, low-SWaP, secure processing—from components to subsystems—and in the "content value" embedded across many defense programs. This gives it a kind of "niche technology supplier" position. But it faces both larger peers and pressure from customers' in-house design teams and lower-cost alternatives. The company discloses plainly that customers may choose lower-cost solutions or re-insource products that were previously outsourced.

A good company in a good industry, or an excellent company in a poor industry. My judgment is: the industry's direction is sound, but MRCY is not yet a proven "good company" within it; it looks more like a "recovery-stage company in a good industry."

Industry attractiveness score: 3/5.

Moat, Management, and Capital Allocation

Moat Analysis

Brand advantage: limited. This is not a consumer-facing brand business, and the brand itself is not the core moat. Its "brand" is reflected more in primes' and military customers' recognition of its reliability, mission-critical processing, and security capabilities. The company says its customers include nearly all the top A&D primes, and that it is embedded in more than 300 programs. This "brand reputation" has value, but it is not the same as a consumer brand that can raise prices freely.

Cost advantage: not evident. The history of gross margin and program-execution volatility shows the company lacks a stable, strong cost advantage. The FY2024 gross-margin collapse demonstrates that once contract estimates and manufacturing execution slip out of control, a so-called "high technology barrier" does not automatically translate into high profit.

Scale advantage: weak. Mercury has accumulated expertise in niche areas, but its scale is not an advantage relative to large defense-electronics and platform suppliers. The company itself admits that larger competitors have more resources and broader product portfolios.

Network effects: none.

Switching costs: moderate. Once designed into a defense platform or program, the hardware, software, and secure-processing solution is not easily replaced, because doing so involves re-qualification, certification, reliability, delivery risk, and time cost. This "design-in + qualification + mission-critical reliability" constitutes a moderately strong switching cost.

Channel advantage: limited. Its channel is reflected more in long-term relationships with primes, government labs, and program offices than in retail or consumer channel barriers. On the contrary, the company stresses that it must continually raise its visibility within primes, government labs, and government-funded labs, or its design wins will suffer.

Patents, licenses, regulatory barriers: moderate. The military business inherently carries export controls and security-clearance, industrial-security, and cybersecurity requirements. The company discloses that many of its facilities and employees require security clearances and must comply with CMMC, NISPOM, and similar requirements. These requirements raise the barrier to entry but do not prevent equally compliant large rivals from entering.

Data advantage: weak.

Corporate culture or operating capability: once a weakness, now in repair. The FY2024 challenged programs, the immature program-management system, and the suspension and restart of the Common Processing Architecture all show that the past few years' operating capability did not constitute a moat and was at one point a shortcoming. Management has seen progress in organizational simplification, plant capability, supply chain, and working capital, but whether this can settle into a durable capability still needs time to verify.

Capital-allocation capability: historically average, recently more disciplined. Since 2014 the company has completed 15 acquisitions, deploying roughly $1.4 billion of capital, and the balance sheet still carries $943 million of goodwill and $185 million of net intangible assets. This shows a classic acquisition-driven expansion path, but looking back, GAAP earnings, gross margin, and shareholder returns were all unimpressive. On the positive side, FY2025 had no active repurchase program and no dividend; the recent acquisitions (Star Lab, SolderMask) were small in scale and look more like capability and capacity bolt-ons than fresh large bets.

My judgment. Mercury's moat exists, but is not wide; more precisely, what it has is a narrow moat built on qualification / design-in / security compliance / engineering integration, not a wide moat that lets it earn high ROIC easily over the long run. In recent years this moat even narrowed at one point due to operating missteps.

Moat strength score: 2/5.

Management and Capital Allocation

Fact. The current CEO, Bill Ballhaus, served first on an interim basis in June 2023 and formally became CEO in August; CFO David Farnsworth joined in July 2023. On governance, there are some positive signals: 8 of 9 board members are independent, with a relatively large number of new directors over the past five years; there are clawback, anti-hedging/anti-pledging, and stock-ownership guidelines. The negatives are: the CEO also serves as chairman, and the board remains a classified board; and as of August 2025, directors and officers together held only about 1.4%, so their economic alignment with shareholders is not strong. Ballhaus himself is constrained by unvested options and similar arrangements, and his disclosed beneficial holdings exercisable within 60 days are under 1%.

Judgment on management's "honesty, rationality, and long-term orientation." I give a neutral-to-cautious assessment. On the positive side, the current management has acknowledged the challenged programs, working capital, and manufacturing-execution issues more directly than the prior team, and continues to talk about margin, cash flow, organizational simplification, and capacity improvement. The FY2024 annual report even described the number of challenged programs, the progress in addressing them, and their cash impact in fairly specific terms. The negative is that this team's long-term track record is not yet long enough, and the company still faces a securities class action and derivative litigation/investigations.

Whether capital allocation has been excellent. Historically, no. By results, the acquisition-built balance sheet has accumulated a large amount of goodwill and intangibles, while GAAP earnings and returns across FY2023–FY2025 were poor; the company's five-year shareholder return also significantly underperformed the SPADE Defense Index and its self-defined peer group. On cumulative 2020–2025 return alone, Mercury was 66.5, the SPADE Defense Index 254.7, and the peer group 286.2. Of course, share price is not the same as intrinsic value, but it at least shows that past capital allocation and operating execution did not turn "scale growth" into "sustained growth in per-share value."

Whether recent capital allocation is more rational. The past year has been much more disciplined than before. FY2025 had no active repurchase and no dividend; in the first nine months of FY2026 there was roughly $15 million of cash outflow for "retirement of common stock," but the FY2025 annual report states clearly that FY2025 had no active repurchase program, so this looks more like tax/equity-settlement activity than large-scale buybacks. Meanwhile, the company has focused on working-capital release, capacity improvement, and small bolt-on acquisitions, which is steadier than the "acquisition-driven growth" of earlier years.

Equity compensation and dilution. The FY2025 proxy materials show an equity-compensation burn rate of roughly 1.37% for FY2025, with a three-year average of about 1.80%; in addition, as of August 2025 there were still 934,000 options with a strike price of $45 and a remaining term of about 2.47 years that had not yet vested. For a company already trading at a high valuation, dilution is not catastrophic, but it is not a trivial matter to ignore either.

Management and capital-allocation score: 2/5.

Financial Quality and Owner Earnings

Financial Quality

The table below uses verified data where possible to show key metrics for FY2021–FY2025 and trailing to Q3 FY2026; for items I could not fully extract and verify in this round, I do not fabricate.

In the table, FY2021–FY2025 revenue, operating income, net income, long-term obligations, and equity come from the company's annual reports; gross margins come from each year's annual report; FY2023–FY2025 operating cash flow and free cash flow come from the company's annual reports and accompanying financial disclosures; the TTM data are calculated on a trailing basis from FY2025 and FY2026 Q3.

How I read this table. First, revenue has not formed a strong, smooth compounding trajectory. From FY2021 to FY2025, revenue went from $924 million to $912 million, with a clear contraction in FY2024 along the way. Second, the deterioration in gross margin and operating margin is very clear, showing that the company did not display the typical characteristics of a high-quality industrial-technology company over the past few years. Third, cash flow looks much better than net income, but this reflects both large depreciation and amortization and the help of working-capital release, so one cannot simply extrapolate FY2025's high free cash flow as the new normal.

Are profits real cash profits, or accounting profits. The answer is: both are biased, but in different directions. GAAP profit is depressed by large amortization, litigation, restructuring, and similar items, so "net income" may understate part of the economic earnings; on the other hand, about 47% of FY2025 revenue comes from long-term contracts recognized over time, and the "total cost estimates" on fixed-price over-time contracts are listed as a critical audit matter, so profit in certain periods can be distorted by the subjectivity of estimates. For a company like this, I trust cash flow more than quarterly profit; but even looking at cash flow, one must distinguish the "operating improvement" component from the "one-time working-capital release" component.

Does growth require heavy capital investment. Historically, what it needs is not only equipment capex, but more importantly working capital and program-execution tie-up. In 2024 and 2025 the company kept "releasing working capital, reducing unbilled receivables, and improving inventory and delivery" as core tasks. The Q2 FY2026 investor materials show net working capital of roughly $414 million on the company's basis, down about $61 million year over year; this shows that prior growth and program execution had tied up a large amount of cash.

Financial leverage and viability. As of March 27, 2026, the company had cash of roughly $331.8 million, long-term debt of $591.5 million, and net debt of about $260 million; total debt/equity was roughly 40%, and the current ratio about 3.19. This is not a dangerous balance sheet, but it is by no means a net-cash "coast to win" position either. On a rough trailing basis, net debt / trailing adjusted EBITDA is about 1.7x, which is acceptable on an adjusted-EBITDA basis; but on trailing GAAP operating income, interest coverage remains on the weak side. In other words, the company is currently viable, but it does not have the financial slack to ignore execution missteps.

Inventory, receivables, and payables. As of 2026 Q3, inventory rose from $332.9 million at the end of FY2025 to $361.7 million; accounts receivable plus unbilled receivables fell from about $388.1 million to about $365.0 million; accounts payable rose from $79.12 million to $104.1 million. This shows the company is indeed converting some unbilled receivables into cash, but inventory remains high, and the cash-flow improvement is not entirely free of fragility.

Whether there are signs of fraud, aggressive accounting, or earnings manipulation. I see no hard evidence pointing directly to "fraud," but there are three red flags that must be faced squarely: first, fixed-price contract estimates carry strong subjectivity and have already been listed by the auditor as a critical audit matter; second, the company has experienced large swings in estimates and gross margin due to challenged programs, production halts, and yield/manufacturing issues; third, the company is still working through a securities class action and derivative litigation. For a conservative investor, this is already enough to demand a higher discount.

Owner Earnings Analysis

Conservative basis. I use a relatively conservative Owner Earnings basis: operating cash flow minus all capital expenditures. I do not loosen it further because Mercury is still in recovery, making it hard to split capex cleanly into "maintenance" and "expansion"; in addition, given that equity compensation is a real economic cost, I am unwilling to aggressively treat all non-cash expenses as "fully distributable" in Owner Earnings.

TTM estimate. FY2025 operating cash flow was roughly $138.9 million, and free cash flow roughly $119.0 million; in the first nine months of FY2026, operating cash flow was roughly $60.24 million and capex roughly $20.71 million, corresponding to free cash flow of roughly $39.52 million; the prior-year first nine months had free cash flow of roughly $85.07 million. Therefore, trailing twelve-month free cash flow / conservative Owner Earnings is roughly: 119.0 + 39.5 - 85.1 = $73.4 million.

Corresponding valuation. At a market cap of roughly $6.71 billion, the current price corresponds to about 91–92x conservative Owner Earnings; spread across the current roughly 60.04 million shares outstanding, conservative Owner Earnings per share is about $1.22, and the current share price is more than 90x that. If equity compensation is treated as an economic cost and discounted further, the true multiple only goes higher, not lower.

The relationship between Owner Earnings and net income. For the five years FY2021–FY2025 combined, free cash flow was roughly $90.1 million, while combined net income was roughly -$130.5 million. This shows that: on the one hand, GAAP net income did understate part of the economic cash capability; on the other hand, Mercury's free cash flow is not the elegant pattern of "stably exceeding net income every year," but is clearly affected by swings in working capital and the pace of recovery. Therefore, I will not treat FY2025's $119.0 million of FCF as a fully verified new normal.

Intrinsic Value and Margin of Safety

Intrinsic Value Estimate

Owner Earnings Discount Method

The following valuation is an assumption, not a fact. I deliberately use a conservative framework, because this company's biggest risk is not short-term volatility but "an operating recovery that falls short of expectations + a return from a high valuation."

The key basis for these ranges is: current trailing Owner Earnings of roughly $73 million; the company's own statement of its long-term targets is a low-to-mid 20% adjusted EBITDA margin and 50% FCF conversion. If revenue reaches the $1 billion to $1.1 billion range over the next few years, then even at a 22%–24% EBITDA margin times 50% FCF conversion, shareholder free cash flow would generally be only around $110 million to $130 million, rather than several hundred million. In other words, for the current share price to be supported by fundamentals, future cash flow must be far higher than the mid-term target profile management itself implies. This is the core reason for my "Avoid."

Relative Valuation Method

MRCY's current static valuation (rough, on a trailing basis):

• P/S about 6.9x

• P/B about 4.5x

• P/FCF about 91x

• EV/Adj. EBITDA about 45–46x

• P/E: not applicable / negative (data sources show a negative P/E)

Compared with stronger peers. Curtiss-Wright's current P/E is about 52.8x, which does not look cheap either; but it achieved record sales, earnings, and free cash flow in 2025, with FY2025 sales of roughly $3.5 billion and free cash flow of roughly $554 million. Teledyne's current P/E is about 31.3x, and its 2025 operating cash flow was roughly $1.191 billion. In other words, high-quality defense/industrial-electronics companies carry high valuations overall, but their high valuations are backed by already-delivered high margins and strong cash flow; whereas MRCY currently carries a valuation close to that of high-quality companies, while still proving whether it can become a high-quality company again.

My conclusion. Relative valuation does not give MRCY the excuse that "peers are all expensive, so it is reasonable too." For a long-term owner, what truly matters is: are you buying already-proven high-quality cash flow. On that basis, MRCY is not cheap at the current price.

Asset or Liquidation Value Method

As of 2026 Q3, shareholders' equity was roughly $1.478 billion, of which goodwill was roughly $943 million and net intangible assets roughly $185 million. Roughly speaking, tangible net assets are only about $350 million, or about $5.8 per share. This shows that: first, this is not the kind of asset-based stock that liquidation value can backstop; second, the large goodwill and intangibles formed by past acquisitions mean book value offers weak protection to a conservative investor. So the asset method tells me only one thing: the current price is almost entirely paying for future earning power, not buying existing assets at a discount.

Valuation Conclusion and Buy Range

Conservative intrinsic value range: $18–25 per share Fair intrinsic value range: $35–50 per share Optimistic intrinsic value range: $60–80 per share

Current price relative to intrinsic value: At a current price of roughly $112.87, the current price has no discount to the conservative, fair, or optimistic valuations, but rather a clear premium. Even on an optimistic midpoint of roughly $70, the current price is still about 60% higher.

The margin of safety I require: Given contract estimates, execution recovery, litigation, customer concentration, and dilution, I would require a margin of safety of at least 30%–40%.

Ideal buy price range: $25–35 This range roughly equates to a conservative discount to "fair value," and leaves room for execution to fall short.

Acceptable holding price range: $35–55 The premise is that free cash flow keeps improving over the next 2–3 years, and that the margin recovery is verified by financial data.

Clearly overvalued price range: above $80; the current $112.87 is especially so. This is my view, not market consensus. The market may keep awarding a higher valuation, but that already approaches the trading logic of "prepaying for years of flawless execution," not the logic a long-term owner favors.

Margin-of-Safety Judgment

Is the current price cheap enough: No. The most fragile assumption in the valuation: that the company can smoothly push the EBITDA margin into the low-to-mid 20% range and stably deliver 50% FCF conversion. If growth falls short: returns are likely to become low single digits or even negative. If margins decline: the current valuation is hard to justify. If the valuation multiple compresses: it would produce a substantial, permanent loss of capital. Is this a "good company at a bad price": more accurately, it is "a company in recovery at a deeply unconservative price." Is it worth waiting: Yes. For a conservative investor, waiting is not missing out, but avoiding overpaying today for "future improvement."

Risks, Comparisons, and Final Conclusion

Risks and the Bear Case

The most important risks:

• Competitive risk. The company itself admits that larger rivals in some markets have stronger resources, and customers may insource designs or choose lower-cost alternatives.

• Technology and product-substitution risk. Commercial server vendors and new entrants may raise military customers' acceptance of "cheaper alternatives."

• Fixed-price contract / EAC risk. This is one of the most central, internally generated risks behind Mercury's financial volatility.

• Customer and budget risk. Roughly 97% of revenue is defense-related, and customers are concentrated among a few primes and government customers.

• Supply-chain and manufacturing risk. FY2024 saw production halts, scrap, and quality and manufacturing-execution problems.

• Leverage and interest-rate risk. The debt is not dangerous, but it is enough to compress flexibility if execution falters again.

• Governance and legal risk. The securities class action and derivative litigation/investigations are still proceeding.

• Goodwill-impairment risk. Goodwill and intangibles are a large share of assets, and if the earnings recovery falls short, future impairment remains possible.

• Overvaluation risk. This is the most direct and realistic risk at present.

The strongest counterargument: why this investment may be wrong. The bear case's most compelling view is not "defense demand is poor," but: Mercury is not a misjudged high-quality compounder, but a turnaround the market is trading as a high-quality compounder. If that judgment holds, then the risk of buying today is not that the business disappears, but that: first, the margin recovery only reaches "ordinary," yet is priced as "excellent"; second, a large part of the free-cash-flow improvement comes from working-capital recovery rather than structural high cash returns; third, once market sentiment switches from the "recovery story" back to "quality verification," the share price will see multiple compression disproportionate to the fundamentals.

What facts, if they appear, should make me admit I am wrong. If the following facts appear over the next 2–3 years, I will admit that today's "Avoid" was too conservative: first, the company sustainably pushes the adjusted EBITDA margin to 20%+, rather than a short-term spike; second, annual Owner Earnings/FCF rises stably above $150 million, and not by way of a one-time working-capital release; third, inventory, unbilled receivables, and program estimates no longer deteriorate repeatedly; fourth, the litigation and governance issues conclude at low cost, and the company does not expose similar control problems again. This part is an inference and tracking framework, not fact. Its support comes from the company's disclosed long-term margin/FCF targets and current operating obstacles.

The largest permanent-loss scenario. If over the next few years the company can only sustain "mid-to-low double-digit EBITDA margins + ordinary cash conversion," while the market re-rates it from a "high-expectation turnaround" to an "ordinary defense-electronics supplier," then even if the business does not collapse, the share price could fall more than 50% over the long run from valuation reversion. This is the permanent loss of capital I worry about most.

Comparison with Other Opportunities

Versus stronger competitors in the industry. If I had to choose between MRCY and Curtiss-Wright, from a long-term business owner's perspective I would clearly favor the latter. Curtiss-Wright has already proven its operating quality with record sales, profit, and free cash flow in 2025; Mercury is still in the "is the recovery sustainable" verification phase.

Versus a broad-market index. The S&P 500 ETF represented by SPY currently trades at roughly $759.57; it is certainly not cheap either, but it offers diversification and lower single-company execution risk. On my valuation framework for MRCY, MRCY currently does not offer risk compensation clearly above a broad-market index.

Versus the risk-free rate. The U.S. 10-year Treasury yield is most recently roughly 4.47%. For a balanced, conservative investor, if a high-volatility single-stock investment's expected return cannot be significantly above 4.47%, there is no sufficient reason to bear its company-specific risk. On my valuation framework, MRCY's neutral expected return at the current price does not meet this requirement.

If I could hold only 5 assets, does it qualify for the portfolio. No. Not because the industry is poor, but because of "insufficient certainty + excessive valuation." Long-term portfolio slots should be reserved for companies that are understandable, verifiable, with stronger distributable cash flow, and more disciplined valuations.

Investment Checklist

The table below is an integrated judgment based on the facts and inferences above, not additional fact disclosure.

Final Investment Conclusion

[Final Rating] Avoid

[One-line investment thesis] Mercury Systems is not hard to understand; rather, the current price is selling a not-yet-fully-proven recovery story as if it were a high-quality long-term compounder.

[Core bull case] The long-term demand in the company's arena is not poor; global military spending and defense-electronics demand still provide support. The company has a product stack from components to systems, and is already embedded across more than 300 programs in 35 countries. FY2025 and the first three quarters of FY2026 show operations are indeed improving: revenue has resumed growth, gross margin has recovered, and working capital is declining. Year-end backlog reached $1.4 billion, and in 2026 it secured a large production order for BuiltSECURE servers, showing demand has not collapsed. The current management values execution, cash flow, and organizational simplification more than the prior team, and the direction is right.

[Core bear case] Over the past five years, gross margin, profit margin, and return on capital have clearly underperformed, showing that a "good industry" did not automatically become a "good business." Nearly half of revenue still involves over-time recognition and cost estimates, making financial predictability weaker than it appears. Litigation, derivative claims, and historical governance issues have not fully turned the page. The large goodwill and intangibles mean the aftereffects of past acquisition-driven expansion remain. Most critically: the current valuation is too high for a company still in recovery.

[Key assumptions] Revenue can keep growing over the next few years without a sharp stall. The adjusted EBITDA margin can rise gradually in the direction of management's targets. The FCF improvement comes mainly from better operating quality, not just a one-time working-capital release. There will be no repeat of FY2024-scale challenged programs and manufacturing shutdowns. Litigation and governance issues will not evolve into a major economic loss.

[Fair buy price] $25–35 per share. Basis: a 30%–40% margin of safety on the neutral intrinsic value of $35–50, with additional consideration for contract-estimate, execution, and litigation risk.

[Target holding period] If bought at a reasonable price, at least 5–10 years; but I stress that the current price does not meet the entry requirement for "long-term holding."

[Expected annualized return] This is my estimate, not company guidance. Based on the current purchase price of roughly $112.87:

• Conservative scenario: -10% to -6% per year

• Neutral scenario: -5% to -1% per year

• Optimistic scenario: 0% to +4% per year The core reason is not that the business must deteriorate, but that the current price is too high; even if operations improve, valuation reversion will eat into returns.

[Maximum loss risk] If the operating recovery stalls, margins miss the target, and cash flow is again consumed by working capital, while the valuation multiple compresses, the long-term decline could be in the 50%–70% range. This judgment is an inference, but its logical basis is the current high multiple and the relatively low cash-flow base.

[Tracking metrics] Going forward I will focus on the following metrics: Whether revenue growth truly comes from healthy demand rather than delivery timing. Whether gross margin and adjusted EBITDA margin keep improving. Whether Owner Earnings / FCF stably exceeds $100 million. Changes in inventory, unbilled receivables, and net working capital. The quality of book-to-bill and backlog, not just the absolute values. Whether challenged programs reappear. Whether goodwill/intangibles show signs of impairment. Equity-compensation dilution and changes in share count. The progress of litigation and derivative investigations. Whether the share of high-margin production orders in new orders rises.

[Signals that trigger a reassessment] Several consecutive quarters of stalled gross-margin/cash-flow improvement. Inventory keeps rising while revenue and deliveries fail to keep up. A renewed major manufacturing halt, scrap, or large adverse EAC adjustment. Management shifting back toward large-scale acquisitions. Litigation or investigations exposing new internal-control or disclosure problems. The share price keeps rising while the fundamentals do not improve proportionately.

[Final recommendation] If you look at MRCY "the way you would buy an entire company," then the coolest-headed conclusion today is not "this is a bad company," but: this is a company still in recovery, not yet proven to be a high-quality compounder, while the market price has already run far ahead of the proof. For 10-year-plus, balanced, conservative capital, what matters most is not missing the story, but avoiding overpaying for the story when there is no margin of safety. My recommendation is: put it on the watch list and track margins, Owner Earnings, working capital, and litigation progress; but at the current price, do not treat it as a "cheap good business" in the Buffett value-investing sense.

Open questions and limitations: This report has prioritized the latest annual reports, quarterly reports, IR materials, and authoritative market data where possible; but for some older years' operating cash flow and certain peers' like-for-like EV/EBITDA/ROIC, I have not done a full recomputation, so the relative-valuation section emphasizes direction rather than mechanical precision. Likewise, all intrinsic-value calculations depend heavily on assumptions about future margins and cash-flow conversion, and should be viewed as a "valuation framework" rather than a precise point estimate.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.